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Prevention and treatment of autoimmune diseases 
with plant virus nanoparticles
Roberta Zampieri1,2*, Annalisa Brozzetti3*, Eva Pericolini4*, Elena Bartoloni3, Elena Gabrielli3, 
Elena Roselletti3, George Lomonosoff5, Yulia Meshcheriakova5, Luca Santi6, 
Francesca Imperatori6, Matilde Merlin1, Elisa Tinazzi7, Francesco Dotta8, Laura Nigi8,9, 
Guido Sebastiani8,9, Mario Pezzotti1, Alberto Falorni3, Linda Avesani1†
Plant viruses are natural, self-assembling nanostructures with versatile and genetically programmable shells, 
making them useful in diverse applications ranging from the development of new materials to diagnostics and 
therapeutics. Here, we describe the design and synthesis of plant virus nanoparticles displaying peptides associated 
with two different autoimmune diseases. Using animal models, we show that the recombinant nanoparticles can 
prevent autoimmune diabetes and ameliorate rheumatoid arthritis. In both cases, this effect is based on a strictly 
peptide-related mechanism in which the virus nanoparticle acts both as a peptide scaffold and as an adjuvant, 
showing an overlapping mechanism of action. This successful preclinical testing could pave the way for the devel-
opment of plant viruses for the clinical treatment of human autoimmune diseases.
INTRODUCTION
Viruses are proteinaceous nanoscale structures that have evolved to 
deliver their cargo of nucleic acids efficiently into cells, enabling 
replication and the production of new viruses. This confers a number 
of attractive properties that can be exploited in the fields of materials 
science, electronics, agriculture, and medicine (1). The self-assembly 
of virus capsids from one or more types of coat protein subunit 
forms virus nanoparticles (VNPs) that are homogeneous in size and 
shape. The genetically encoded coat proteins can be modified to 
incorporate new sequences and can be synthesized using rapid and 
scalable manufacturing platforms. Additional functionalities can also 
be introduced by chemical conjugation (1).
VNPs can be based on mammalian viruses or bacteriophages, 
but plant VNPs (pVNPs) share all the beneficial characteristics listed 
above with the further advantage that they are unable to replicate in 
mammals, making them safer for medical applications (2). The 
scalable production of pVNPs can be achieved by molecular farm-
ing in natural plant hosts (3). Thus far, pVNPs have been used for 
bioimaging applications, cancer therapy, and the development of 
vaccines presenting antigens and peptides derived from pathogens 
(3, 4). Another promising medical application of pVNPs is the 
development of therapeutic vaccines displaying immunodominant 
peptides associated with autoimmune diseases, which can be used 
to induce immunotolerance. We investigated the potential of this 
approach by focusing on two common human autoimmune diseases: 
type 1 diabetes mellitus (T1D) and rheumatoid arthritis (RA).
T1D is an organ-specific disease characterized by the destruction 
of pancreatic islet -cells mediated by cellular and humoral immune 
responses (5). These responses target several autoantigens including 
the 65-kDa isoform of glutamic acid decarboxylase (GAD65), which 
has been identified as one of the major T1D autoantigens both in 
humans and in nonobese diabetic (NOD) mice (6). The NOD mouse 
strain is one of the best animal models of human autoimmune 
diabetes and spontaneously develops many of the disease features 
seen in human T1D (7). Preclinical studies in NOD mice have shown 
that protein or peptide vaccines based on GAD65 can prevent 
diabetes (8). However, the role of GAD65 peptides spanning residues 
524 to 543 of the native protein (p524) remains controversial, with 
several reports suggesting a protective role either individually or 
combined with other peptides (9–12). Notably, a challenge with 
p524 triggered the expansion of CD4+ CD25+ Foxp3+ suppressive T cells 
in vitro, and those cells were later able to inhibit diabetes in a cotransfer 
model (10). In silico modeling suggests that the negatively charged 
surface of p524 may help it to bind two major histocompatibility 
complex class II antigen chains and may thus improve its stability (10).
RA is a systemic disease involving the loss of tolerance to various 
citrullinated antigens (13). This results in the activation of autoreactive 
T cells and the production of inflammatory cytokines that lead to 
progressive synovial inflammation. Most patients with RA (50 to 80%) 
are seropositive for two types of autoantibody: rheumatoid factor 
[which recognizes the Fc portion of immunoglobulin G (IgG)] 
and anti-citrullinated protein antibody (ACPA), which recognizes 
citrullinated proteins and peptides (14). Seropositive RA patients 
tend to experience a more severe disease course than seronegative 
patients, with a higher risk of joint erosion and a lower probability 
of disease-free remission in response to conventional therapies (14). 
However, seronegative patients may have a more active form of the 
disease, with similar radiographic damage at presentation and a slower 
treatment response compared to seropositive patients, suggesting 
that seronegative RA may have a worse outcome than previously 
understood (15). We recently demonstrated that pLip1 and pFADK2 
are immunodominant peptides associated with patients seronegative 
for rheumatoid factor and ACPA, suggesting that immunization 
with these peptides may allow the treatment of seronegative RA (16).
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To investigate the suitability of pVNPs as a means to address T1D 
and RA, we designed pVNPs based on two different plant viruses: 
cowpea mosaic virus (CPMV) and tomato bushy stunt virus (TBSV) 
(17, 18). CPMV has an icosahedral capsid, 30 nm in diameter, 
comprising 60 copies each of the large and small coat protein 
subunits. For the CPMV system, we used genome-free virus-like 
particles (VLPs) that have the same structural characteristics as the 
parent virus. In contrast, TBSV was produced as an infectious virus. 
TBSV also has an icosahedral, 30-nm capsid but is composed of 180 
subunits of a single capsid protein. We used genetic engineering to 
express immunodominant peptides associated with T1D (p524) on 
CPMV and RA (pLip1 and pFADK2) on TBSV. We then tested the 
ability of the pVNPs to prevent T1D or reduce the severity of RA in 
appropriate animal disease models: NOD mice for T1D, and dilute, 
brown, and non-agouti (DBA) mice for RA, based on their suscep-
tibility to collagen-induced arthritis (CIA) (19).
RESULTS
Production of self-assembling VNPs in plants
CPMV-based VLPs were produced in the leaves of Nicotiana benthamiana 
plants by agroinfiltration. The sequence of the CPMV small coat 
protein subunit (VP60) was engineered to display the GAD65 
peptide p524 on the outer surface of the assembled particle. The 
wild-type p524 sequence (SRLSKVAPVIKARMM) has a suboptimal 
isoelectric point (pI) for display (17), so the sequence was adjusted 
(p524opt: DSRLSKVAPVIKARMMED) to achieve a pI of 8.59. The 
p524opt sequence was inserted within the B-C loop of the small 
coat protein subunit in pEAQ-HT-VP60 to produce vector pEAQ-
HT-VP60.p524opt. N. benthamiana leaves were infiltrated with 
Agrobacterium tumefaciens carrying pEAQ-HT-VP60.p524opt (or 
pEAQ-HT-VP60 as a control) together with another A. tumefaciens 
strain carrying pEAQ-HT-24K, encoding the large coat protein subunit.
Extracts of leaves infiltrated with pEAQ-HT-24K plus either 
pEAQ-HT-VP60.p524opt or pEAQ-HT-VP60 were prepared 6 days 
post-infiltration (dpi) for analysis by Western blot using an anti- 
CPMV antiserum (Fig. 1A). This revealed the presence of the 
processed large and small coat proteins in both samples, with the 
small coat protein derived from pEAQ-HT-VP60.p524opt migrating 
more slowly than that from pEAQ-HT-VP60, consistent with the 
presence of the p524opt peptide. The virus particles were isolated 
from N. benthamiana leaf tissue, resulting in yields of 100 mg of 
purified CPMV per kilogram of leaf fresh weight (LFW) and 10 mg 
of purified CPMV.p524opt per kilogram of LFW as determined by 
Fig. 1. Characterization of pVNPs derived from CPMV. Wild-type particles (wt CPMV) and particles displaying the p524opt peptide (CPMV.p524opt) were characterized 
and compared after purification from N. benthamiana leaves. Gel electrophoresis under denaturing conditions was followed by (A) silver staining and (B) Western blot 
analysis to assess the purity of the particles. The small subunit (S) and large subunit (L) were detected in both cases. The structural conformation of the purified particles 
was confirmed by TEM (C and D) and DLS analysis (E).
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a silver staining (Fig. 1B), which also indicated that the p524opt 
peptide was displayed on the surface of the particles. Transmission 
electron microscopy (TEM) showed no structural differences between 
CPMV and CPMV.p524opt, confirming that the peptide did not 
interfere with self-assembly (Fig. 1, C and D). Likewise, dynamic 
light scattering (DLS) analysis showed that CPMV and CPMV.
p524opt had a similar hydrodynamic radius (Fig. 1E).
TBSV-based pVNPs were also produced in N. benthamiana 
plants, following the engineering of the surface-exposed C terminus 
of the coat protein to display pLIP1 (ASVLANVAQAFE) or pFADK2 
(AKVLANLAHPPA). In vitro transcribed genomic RNA encoding 
the wild-type TBSV and modified TBSV.pLIP1 and TBSV.pFADK2 
coat proteins was used for the infection of N. benthamiana plants. 
Infected plant material was collected when symptoms of virus 
disease appeared, and the pVNPs were purified and analyzed by 
Western blot and silver staining as above (Fig. 2A). We achieved 
yields of 65 mg/kg LFW for wild-type TBSV, 72 mg/kg for TBSV.
pLIP1, and 114 mg/kg for TBSV.pFADK2. TEM (Fig. 2, B to D) and 
DLS (Fig. 2E) analysis revealed that the modified particles assembled 
in the same manner as the wild-type virus.
CPMV.p524opt achieves the partial prevention 
of autoimmune diabetes in mice
We treated NOD female mice before the onset of insulitis by intra-
peritoneal injection with synthetic peptides (p524 and p524opt), 
pVNPs (one or two doses of CPMV.p524opt), or wild-type CPMV 
as a control (Fig. 3 and fig. S1). Neither of the peptides altered the 
disease course, but the two doses of CPMV.p524opt nanoparticles 
induced a protective effect compared to the other treatments (overall 
P = 0.01, log-rank test). More specifically (Fig. 3A), Kaplan-Meier 
analysis showed a significantly lower progression to diabetes for 
NOD mice treated with two doses of CPMV.p524opt compared to 
wild-type CPMV (P = 0.04), p524opt (P = 0.008), or p524 (P = 0.001). 
The untreated group showed a survival curve identical to the wild-
type CPMV group: first clinical symptoms at 71 days of age, 30% 
disease prevalence at 121 days, 50% at 142 days, and 80% at 168 days. 
Comprehensive statistical comparisons among treatments are pro-
vided in fig. S1.
Nondiabetic NOD female mice were examined for islet infiltration 
at different time points (5, 10, and 27 weeks after the treatment). 
Histological analysis of pancreas samples showed a significant overall 
Fig. 2. Characterization of TBSV.pLip1 and TBSV.pFADK2. Wild-type particles (wt TBSV) and particles displaying the pLIP1 and pFADK2 peptides (TBSV.pLIP1 and TBSV.
pFADK2, respectively) were analyzed after purification from infected N. benthamiana plants. Gel electrophoresis under denaturing conditions was followed by silver 
staining of the purified particles (A). The structural conformation of the purified wt TBSV (B), TBSV.pLIP1 (C), and TBSV.pFADK2 (D) particles was assessed by TEM and DLS 
analysis (E).
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difference in insulitis score among the different treatment groups 
(Kruskal-Wallis test, P < 0.0001). More specifically (Fig. 3B), a sig-
nificant difference was observed at all three time points between 
animals treated with CPMV.p524opt and those treated with the 
wild-t ype virus (P < 0.0001), as well as at 10 and 27 weeks between 
animals treated with CPMV.p524opt and those treated with p524 
(P < 0.0001).
Foxp3+ regulatory T (Treg) cells play a key role in self-tolerance, 
so we investigated whether CPMV.p524opt increased the number 
of Foxp3+ cells in the treated mice. Immunofluorescence analysis of 
pancreatic sections revealed a significantly lower (P = 0.034) number 
of Foxp3+ cells within and around islets in mice treated with CPMV.
p524opt compared to those treated with wild-type CPMV (Fig. 4A).
Serum from all treatment groups was analyzed to identify soluble 
mediators, and the distribution among groups was determined by 
two-way orthogonal partial least squares discriminant analysis (OPLS- 
DA), indicating four distinct groups matching the different treatments 
(Fig. 4B). The corresponding scatter plot (Fig. 4C) revealed two 
principal components. The first (P1; horizontal axis) explains 34.5% of the 
variability and separates CPMV.p542opt 2 treatments + wt CPMV from 
CPMV.p524opt single treatment + p524. This reflects the activation of 
soluble mediators with different profiles depending on the treatment: 
mainly KC (keratinocyte chemoattractant), IL1a (interleukin-1a), 
IL13, eotaxin, and IL9 for wt CPMV but mainly MCP1 (monocyte 
chemoattractant protein 1), MIP1B (macrophage inflammatory 
protein 1B)/1A, IL12, IL10, RANTES, IFN (interferon-), and IL2 
Fig. 3. Partial protection from autoimmune diabetes in NOD mice treated with CPMV-derived particles displaying the p524opt peptide. The survival curves of 
groups treated with CPMV-derived particles indicate partial protection from the onset of diabetes in mice treated twice with CPMV.p524opt (blue line) compared to all 
the other groups: wt CPMV (green line), p524opt synthetic peptide + IFA (red line), and p524 synthetic peptide + IFA (gray line). The single administration of CPMV.
p524opt (yellow line) did not prevent the onset of diabetes. The x axis indicates the number of days after the first treatment (A). The histopathology of pancreatic islet 
cells was determined in subsets of the treated mice by counting infiltrated cells. After 5 and 10 weeks of treatment (5w and 10w) and at the end of the treatment, some 
animals were euthanized to characterize the progression of the disease; CPMV.p524opt is the animal group that received double treatment (B).
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for CPMV.p524opt 2 treatments; the CPMV.p542opt 1 treatment 
shows the non-activation of the aforementioned cytokine profile rather 
than a specific signature. The second (P2; vertical axis) explains 10.2% 
of the variability and seems to correlate with the concentration of p524.
TBSV.pLIP1 and TBSV.pFADK2 reduce the severity of RA 
in mice
The first signs of arthritis in DBA mice appeared 28 days after 
collagen injection, and 100% of the immunized mice exhibited 
arthritis after 33 days. Figure 5 shows the effect of pVNPs and 
synthetic peptides administered starting 28 days after immuniza-
tion compared to a negative control group treated with saline. The 
group treated with TBSV.pFADK2 (Fig. 5A) demonstrated a lower 
clinical score (days 31 to 60 after immunization) compared to mice 
treated with pFADK2 plus incomplete Freund’s adjuvant (IFA), 
which is a remarkable improvement given the comparable disease 
symptoms on day 28. The effect on mice treated with TBSV.pFADK2 
was similar to that of the positive control group injected with dexa-
methasone. However, at the end of the immunization period (day 
28), TBSV.pFADK2 was administered only to those mice whose dis-
ease severity was higher than that of control group mice, thus sup-
porting the greater efficacy of TBSV.pFADK2 (Fig. 5A).
Even better results were observed in the group treated with TBSV.
pLIP1 (Fig. 5B). As above, the groups receiving the TBSV.pLIP1 
and pLIP1 + IFA formulations had the same clinical arthritis score 
28 days after immunization. However, the administration of TBSV.
pLIP1 completely abolished all clinical signs of arthritis at the end 
of treatment, whereas mice treated with pLIP1 + IFA had similar 
arthritis scores on day 60 to mice treated with dexamethasone, 
although the former group was characterized by more severe arthritis 
at the beginning of treatment. Last, the comparison of TBSV.
pFADK2, TBSV.pLIP1, and wild-type TBSV revealed that even 
wild-type TBSV induced partial protection (Fig. 5C), as also seen 
for the wild-type CPMV particles in the T1D model (Fig. 3A). 
Treatment with TBSV.pLIP1 was the most effective, eliminating all 
signs of arthritis by the end of the treatment period (Fig. 5B). The 
efficacy of TBSV.pFADK2 appeared similar to the wild-type TBSV, 
but it is important to consider that, by day 28, the group treated 
with TBSV.pFADK2 had a higher clinical score than the group 
treated with wild-type TBSV. These data support the hypothesis that 
intrinsic virus structures boost the regulatory activity of immuno-
dominant peptides and work as an adjuvant.
Given the positive effect of the pLIP1 and pFADK2 peptides in 
mice when presented on the pVNPs, we tested the hypothesis that 
both peptides can induce the expansion of immunomodulatory cell 
populations. We therefore evaluated a panel of proinflammatory 
and anti-inflammatory cytokines in the serum, joints, and lymph 
nodes of the treated mice (Fig. 6C). We observed a general deple-
tion of proinflammatory cytokines such as TNF (tumor necrosis 
factor–), IL17A IL1, and IFN in the groups treated with TBSV 
and the synthetic peptides pLIP1 and pFADK2 + IFA, but treatment 
with TBSV.pLIP1 was associated with a more effective depletion of 
all proinflammatory cytokines in the lymph nodes and of TNF and 
IL17A in serum, with no effect on cytokine levels in the joints. Fur-
thermore, pFADK2 + IFA markedly reduced the levels of TNF, 
IL17A, IL1, and IFN in the lymph nodes and IL17A in the serum, 
as well as achieving a general trend toward the depletion of proin-
flammatory cytokines in the joints (significant in the case of IFN). 
On the other hand, treatment with TBSV.pFADK2 strongly reduced 
Fig. 4. Treg cell numbers and global cytokine profiles in NOD mice treated with 
CPMV-derived particles. Mice treated with two doses of CPMV.p524opt and mice 
treated with the wt CPMV particles show no significant difference in the number of 
Foxp3+ T cells (A). OPLS-DA score scatter plot (B) and loading scatter plot (C) of the 
preclinical study model (explained variance = 44.7%) with two doses (blue square) or 
one dose (white circle) of CPMV.p524opt, with the wt CPMV (red triangle) and with 
p524 synthetic peptide (yellow triangle). OPLS-DA model = 3 + 6 + 0, R2X(cum) = 0.919, 
R2Y(cum) = 0.878, Q2(cum) = 0.764. In the loading scatter plot (C), the green dots show 
the contribution of each cytokine to the statistical classes listed above. The global 
cytokine profile shows the activation of different cytokines in mice treated twice with 
wt CPMV (red triangle) and CPMV.p524opt (blue square). Mice treated twice with the 
synthetic p524opt peptide (yellow triangle) or once with CPMV.p524opt (green circle) 
do not show specific activation profiles compared to the other treatment groups.
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the levels of IL17A in lymph nodes and serum and IL1 and IFN in 
lymph nodes.
Treatment with dexamethasone resulted in the more effective 
modulation of all proinflammatory cytokines in lymph nodes, as well 
as TNF, IL1, and IFN in joints, and TNF in serum. Moreover, 
the administration of dexamethasone and pFADK2 + IFA induced 
a therapeutic effect driven by TGF (transforming growth factor–), 
a pleiotropic cytokine with potent regulatory and inflammatory 
activity. In contrast, TBSV.pLIP1 and TBSV.pFADK2 induced a more 
direct activation of IL10. Wild-type TBSV also partially induced the 
production of TGF and IL10 in serum (Fig. 6B). The cytofluorimetric 
analysis of Treg (CD25+/Foxp3+) cells in lymph nodes showed that 
TBSV.pFADK2 strongly increased the proportion of these cells, and 
a similar effect, although less pronounced, was observed for TBSV.
pLIP1 and pLIP1 + IFA, whereas dexamethasone showed the most 
potent effect overall.
DISCUSSION
The development of VNPs for medical applications has thus far 
focused mainly on the delivery of drugs and imaging molecules to 
particular target cells (20–22). However, the ability of VNPs to 
display peptide antigens or epitopes has also resulted in their appli-
cation as vaccines, for example, the display of pathogen-derived 
peptides as an active immunization strategy against infectious 
diseases or the display of self-antigens found on cancer cells as a means 
to turn the immune system against tumors (22). The investigation 
and preclinical testing of these approaches has generated a body of 
evidence that VNPs also have immunomodulatory effects: For 
example, pVNPs have been shown to suppress cancer cell prolifera-
tion and metastasis through the activation of both local (tumor 
microenvironment) and systemic anticancer immune responses in-
volving the modulation of cytokine secretion and the activation 
states of different immune cell populations (21, 22). We therefore 
hypothesized that pVNPs displaying autoimmune disease self-antigens 
may also be able to modulate the immune system to induce tolerance 
and therefore either prevent or treat diseases such as T1D and RA.
We engineered the coat proteins of CPMV and TBSV to display 
immunodominant peptides associated with T1D (p524opt) and RA 
(pLIP1 or pFADK2), respectively. These viruses are similar in shape 
and size, but the density of peptide display is threefold lower in CPMV 
due to the assembly of the virion from two different coat protein 
subunits, compared to the single coat protein of TBSV. Icosahedral 
nanoparticles tend to circulate in vivo for a few hours, whereas fila-
mentous and rod-shaped viruses persist for longer, but the residence 
time in our case should be sufficient to trigger the desired effects 
(23). We found that the presence of p524opt reduced the yield of 
CPMV particles in plants by 10-fold compared to the wild-type virus, 
perhaps due to the loss of stability or promotion of aggregation, 
although we optimized the pI of the recombinant particles (17). In 
contrast, the presence of either pLIP1 or pFADK2 improved the 
yields of TBSV, perhaps by the opposite effect of increasing stability.
We tested the recombinant pVNPs in appropriate mouse models 
of T1D and RA and compared their efficacy to the corresponding 
peptides without a virus scaffold. The peptides were administered 
with an adjuvant, which is necessary to ensure a strong immune 
response, whereas the pVNPs were administered without an adjuvant, 
because the repetitive structure of the virus scaffold is known to 
achieve a similar effect (23). Adjuvants can trigger local or systemic 
reactogenicity, which negatively affects public perception of the 
risk-benefit balance of immunization. In contrast, the safety profile 
of plant viruses is positive, given their ubiquitous presence in the 
environment and especially in all plant-based foods.
The analysis of NOD mice revealed that two treatments with the 
CPMV.p524opt formulation achieved partial protection from the onset 
of diabetes, whereas the free p524opt peptide had no protective 
effect. The protective mechanism induced by CPMV.p524opt did 
not appear to be mediated by Treg cells, given that fewer Foxp3+ cells 
were present around the pancreatic islets of mice treated with the 
Fig. 5. Effect of TBSV-derived particles on the severity of CIA. Arthritic scores in 
each group were assessed every 2 to 3 days starting from days 24 to 59 after immu-
nization. (A) Comparison of saline-treated CIA mice (control) to CIA mice treated with 
dexamethasone, TBSV.pFADK2, or pFADK2 + IFA. (B) Comparison of saline-treated 
CIA mice (control) to CIA mice treated with dexamethasone, TBSV.pLIP1, or pLIP1 + IFA. 
(C) Comparison of saline-treated CIA mice (control) to CIA mice treated with wt 
TBSV, TBSV.pLIP1, or TBSV.pFADK2. Each time point represents the mean arthritic 
score ± SEM (n = 5). Statistical significance was determined by applying the Kruskal- 
Wallis test followed by Dunn’s multiple comparison test. Values of P < 0.05 were 
considered significant. Significance was established for CIA mice treated with 
dexamethasone versus saline-treated CIA mice and for CIA mice treated with TBSV.
pLIP1 versus saline-treated CIA mice.
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pVNP formulation. Similarly, the analysis of recent-onset NOD mice 
treated with the bacterium Lactococcus lactis engineered to secrete 
GAD65370-575 (and the anti-inflammatory cytokine IL10) in the 
gut combined with short-course low-dose anti-CD3 (combi-GAD 
therapy) achieved the stabilization of insulitis, the preservation of 
functional -cell mass, and the restoration of normoglycemia, with 
no significant difference in the number of Foxp3+ cells in and around 
pancreatic islets compared to untreated mice (6). We speculate that the 
positive outcomes we observed may reflect the differential activation 
of cytokines by the various treatment groups, with IL10 and IL2 
playing a major role in the double-dose treatment with CPMV.p524.
The analysis of DBA mice following the establishment of CIA 
provided exciting preliminary evidence that the administration of TBSV 
particles displaying pFADK2 or pLIP1 can achieve the complete 
remission of arthritis signs even if the pVNPs are delivered after the 
onset of disease. CIA in DBA mice is the most commonly used T 
helper cell (TH1)–dependent model of chronic arthritis, because it is 
highly reproducible and allows the antibody-induced effector phase 
of arthritis to be studied in detail. Tolerance to citrullinated proteins 
has been shown in DBA mice, and the prophylactic administration 
of citrullinated filaggrin peptide protected these mice from arthritis 
(24). The administration of a multiepitope citrullinated peptide 
derived from major prevalent autoantigens immediately after the 
induction of disease significantly reduced the severity of symptoms 
in an adjuvant-induced rat arthritis model (25). These results and 
our data support the hypothesis that antigen-specific tolerance can 
be achieved in RA by the repeated administration of peptides that 
cause the immunomodulation of T cell populations involved in the 
immune response (mainly TH1, TH17, and Treg cells) and the down- 
regulation of proinflammatory cytokines. Specifically, we observed 
the depletion of TNF, IL1, IL17, and IFN in the serum, lymph 
nodes, and (to a lesser extent) the joints. These cytokines are the key 
mediators of the innate (TNF), adaptive (IFN), and TH17-mediated 
(IL17) immune responses in RA. The beneficial effect of the pVNPs 
was also associated with the secretion of anti-inflammatory cytokines 
such as IL10 for TBSV.pLIP1 and TBSV.pFADK2, and both TGF 
and IL10 for TBSV.pFADK2, as well as the accumulation of CD25+ 
Foxp3+ Treg cells, which suppress autoreactive lymphocytes either by 
direct contact or by promoting the secretion of TGF and IL10. The 
higher proportion of Treg cells in the lymph nodes of treated mice 
supports the role of this T cell subset in suppressing the immune- 
mediated inflammation that occurs during the pathogenesis of RA (25).
The roles of liprins and FADKs (focal adhesion kinases) in the 
immunopathogenesis of RA are unknown. The liprin family of 
multidomain proteins is required for cell motility on the extracellular 
matrix and the efficient regulation of focal adhesion during cell 
migration (26). The liprin 1 dimer is strongly expressed by lymphatic 
endothelial cells, where it regulates lymphatic vessel integrity (27). 
The pFADK2 sequence was derived from protein tyrosine kinase 2 
(FAK2/PTK2B), which controls cell adhesion, migration, and invasion. 
In murine models of RA, FAK2/PTK2B promotes inflammatory 
angiogenesis, induces synovial fibroblast invasion, and triggers the 
formation of synovial pannus, suggesting a role in the onset and 
progression of synovial hyperplasia (28, 29). The positive effect of 
pFADK2 administration in DBA mice may therefore partially reflect 
the inhibition of synovial hyperplasia, supporting the role of focal 
adhesion kinases in the pathogenesis of RA and the value of peptide- 
driven therapy using adjuvant viral scaffolds.
Together, our results indicate that although immunodominant 
peptides delivered by pVNPs offer a therapeutic benefit in models 
of both T1D and RA, the underlying mechanisms are different, with 
the activation of Treg cells required only in the RA model. This 
shows that the peptides displayed by the pVNP strongly influence 
the immunomodulatory mode of action. However, the virus scaffold 
achieved an adjuvant effect in both cases, perhaps by stabilizing the 
peptide and concentrating multiple peptides in a small area. The 
Fig. 6. Effect of TBSV-derived particles on cytokine profiles and the proportion of CD25+ Foxp3+ cells. (A) The percentage of CD25+ Foxp3+ cells was determined in 
the lymph nodes of non-CIA mice and CIA mice treated with saline, dexamethasone, wild-type TBSV, TBSV.pLIP1, TBSV.pFADK2, pLIP1 + IFA, and pFADK2 + IFA on day 
60 after immunization. Values represent means ± SEM (n = 3; except for non-CIA mice, where n = 2). (B) Levels (pg/ml) of TGF1 and IL10 were determined in the serum of 
non-CIA mice and CIA mice treated with saline, dexamethasone, wild-type TBSV, TBSV.pLIP1, TBSV.pFADK2, pLIP1 + IFA, and pFADK2 + IFA on day 60 after immunization. 
Serum values represent data pooled from five mice. (C) TNF, IL17A, IL-1, and IFN levels (pg/ml) were determined in the serum (S) and lymph node (LN)/joint (J) super-
natants of non-CIA mice and CIA mice treated with saline, dexamethasone, wild-type TBSV, TBSV.pLIP1, TBSV.pFADK2, pLIP1 + IFA, and pFADK2 + IFA on day 60 after 
immunization. Values represent means ± SEM (n = 3). Serum values represent data pooled from five mice. Statistical significance was determined by ANOVA, followed by 
Bonferroni correction. Values of P < 0.05 were considered significant (*). Significance was established for CIA mice treated versus saline-treated + CIA.
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combination of virus scaffold and immunodominant peptides resulted 
in the secretion of IL10, which was more abundant in the serum of 
both disease models after treatment with the pVNP. The requirement 
for both the scaffold and the peptides is shown by the negligible 
increase in IL10 levels in response to either the wild-type virus or 
the synthetic peptide formulation.
MATERIALS AND METHODS
Gene cloning and transient expression
The sequence encoding the p524opt peptide (DSRLSKVAP-
VIKARMMED) (30) was codon-optimized for N. benthamiana and 
transferred to vector pEAQ-HT-VP60 as previously described (31) 
to generate the recombinant plasmid pEAQ-HT-VP60.p524opt. The 
sequences encoding the peptides pLIP1 (ASVLANVAQAFE) and 
pFADK2 (AKVLANLAHPPA) (16) were likewise codon-optimized 
and transferred to the TBSV expression plasmid as previously 
described (18).
The transient expression of CPMV vectors was achieved by 
introducing pEAQ-HT-VP60.p524opt (or pEAQ-HT-VP60 as a con-
trol) along with pEAQ-HT-24K into A. tumefaciens strain LBA4404 
(32). We manually infiltrated four leaves in 3 or 30 N. benthamiana 
plants depending on the scale of expression and isolated the pVNPs 
6 dpi. The transient expression of TBSV vectors was achieved by 
in vitro transcription to produce infectious RNAs, which were used 
for the manual infection of two leaves in three N. benthamiana 
plants. Leaves displaying local and systemic infection symptoms 
were pooled and checked for recombinant virus RNA by reverse 
transcription polymerase chain reaction (RT-PCR). Sap was collected 
from the infected leaves 6 to 10 dpi (depending on the construct) 
and used for the secondary large-scale infection of 50 plants. The 
pVNPs were isolated 6 to 10 days later, following the appearance of 
infection symptoms.
Purification of pVNPs
The pVNPs were purified as previously described (33, 34). For CPMV, 
25 to 30 g of infiltrated leaf tissue were extracted (34), and the green 
juice was processed by anion-exchange chromatography (DEAE 
Sephadex A-50 resin) to remove impurities. The flow-through fraction 
was collected and concentrated 30-fold using 100-kDa cutoff Centricon 
tubes. The pVNPs were then isolated from the concentrate by size 
exclusion chromatography using a HiPrep 16/60 Sephacryl S-500 HR 
(ÄKTAprime plus) column. For TBSV, we collected 30 to 40 g of 
mixed symptomatic and locally infected leaves, and the green juice 
was extracted as previously described (18). Briefly, after filtration, 
the extract was incubated in ice for 1 hour and centrifuged at 8000g 
for 15 min at 4°C. The supernatant was collected and centrifuged at 
90,000g for 1 hour at 4°C. The pellet was then resuspended in 50 mM 
sodium acetate (pH 5.3), and the resulting solution was centrifuged 
at 8000g for 15 min at 4°C. The supernatant was collected and stored 
at −20°C.
Western blot, DLS, and TEM analysis
To confirm the presence, integrity, and structure of the pVNPs, total 
soluble protein was extracted from infiltrated leaves and analyzed by 
SDS–polyacrylamide gel electrophoresis and silver staining, Western 
blot (CPMV only), DLS, and TEM as previously described (33). CPMV 
particles were detected using primary polyclonal antibody G49 
diluted to 1:2000 as previously described (33).
Ethics statement
All procedures involving animals conformed to national and inter-
national laws and policies. All animal experiments met the requirements 
of European Union Directive 2010/63, the European Convention 
for Protection of Vertebrate Animals used for Experimental and 
other Scientific Purposes, and National Law 116/92. The protocol was 
approved by the Animal Care and Use Committee of the University 
of Perugia and by the Italian Ministry of Health. All animals were 
housed in the animal facility of the University of Perugia (authori-
zation number 34/2003A).
Animal studies involving NOD mice
Four-week-old female NOD mice were obtained from Charles River 
Laboratories and housed under specific pathogen–free conditions in 
the animal facility at the University of Perugia, with ad libitum access 
to water and food. NOD mice were randomly subdivided into four 
groups. In group 1 (n = 18), CPMV.p524opt [50 g per mouse, re-
suspended in 100 l of phosphate-buffered saline (PBS)] was injected 
twice intraperitoneally, with 2 weeks between doses. In group 2 
(n = 20), wild-type CPMV particles (50 g per mouse, resuspended 
in 100 l of PBS) were administered with the same schedule. In group 
3 (n = 15), synthetic peptide p524 (50 g per mouse, resuspended in 
100 l of PBS plus IFA) was administered with the same schedule. In 
group 4 (n = 15), the same schedule and dosing was used for synthetic 
peptide p524opt. Another group of NOD mice (n = 14) received a 
single dose of CPMV.p524 (50 g per mouse, resuspended in 100 l 
of PBS). A control group was left untreated (n = 20). Mice were mon-
itored for the appearance of clinical signs of diabetes and were euth-
anized when the disease was confirmed by glucosuria.
Animal studies involving DBA mice
Female DBA/1 mice 6 to 8 weeks of age (Charles River Laboratories) 
were maintained under specific pathogen–free conditions as above. 
CIA was induced by the intradermal tail base injection of 100 g of 
chicken type II collagen (Sigma-Aldrich) as previously described (35). 
Five mice per group were immunized on days 0 and 21 to induce ar-
thritis. The onset of disease was confirmed on the day that swelling or 
erythema was observed in any paw, typically 4 to 10 days after the 
second immunization. Each experimental group was treated seven 
times, 5 days apart, starting from day 28 after the first immunization, 
with intraperitoneal injections of saline (200 l per mouse), TBSV.
pLIP1, TBSV.pFADK2, pLIP1 + IFA, and pFADK2 + IFA (all 50 g 
per mouse in 200 l) or dexamethasone (5 g per mouse in 200 l). A 
healthy nonimmunized group (n = 5) was included as a control. CIA 
was assessed using a macroscopic score system based on the visual 
identification of arthritic limbs. The clinical severity of arthritis was 
evaluated as follows: Each mouse was inspected every 2 to 3 days for 
three different parameters: (i) swelling of the hind ankle and foot, 
measured with calipers; (ii) erythema of each leg; and (iii) swelling of 
the fingers. Each of these parameters was assessed by severity and was 
graded from 0 to 4 as shown in fig. S2. The RA index for each mouse 
was expressed as the mean of the three scores from the individual pa-
rameters. At the end of the experiment (60 days), we determined the 
proportion of CD25+ Foxp3+ cells in the lymph nodes and measured 
cytokine titers in the lymph nodes, joints, and serum (see below).
Histopathological analysis of treated mice
For histology and immunohistochemistry, mice were euthanized 5, 
10, and 27 weeks after treatment. The pancreas was removed and fixed 
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in 10% buffered formalin for 20 hours and embedded in paraffin. 
Sections of 5 mm were cut 40 m apart throughout the gland and 
stained with hematoxylin-eosin (Merck) to determine the insulitis 
score using the following grading scale: 0, intact islet; 1, peri-insulitis; 
2, moderate insulitis (<50% of the islet infiltrated); and 3, severe 
insulitis (≥50% of the islet infiltrated). At least 15 islets per pancreas 
were analyzed by two independent examiners as previously described 
(6). Some sections, after deparaffinization and rehydration through 
an ethanol series, were analyzed by double immunofluorescence 
staining for Foxp3 and insulin (36). The number of Foxp3+ cells 
within and around pancreatic islets was determined by manual counting.
Cytokine determination
In the serum of NOD mice, 23 cytokines [IL1, IL1, IL2, IL3, IL4, 
IL5, IL6, IL9, IL10, IL12 (p40), IL12 (p70), IL13, IL17A, eotaxin, 
G-CSF (granulocyte colony-stimulating factor), GM-CSF (granulocyte- 
macrophage CSF), IFN, KC, MCP1 (MCAF), MIP1, MIP1, 
RANTES, and TNF] were quantified using Luminex xMAP tech-
nology (Bio-Plex Pro Mouse Cytokine 23-Plex, Bio-Rad Laboratories). 
To quantify cytokines in DBA mice, joint tissues were pulverized 
and resuspended in 1 ml of lysis medium per 100-mg joint weight 
for 60 min at 37°C, followed by centrifugation to remove debris. 
Lymph nodes were removed, homogenized, and centrifuged as above. 
Supernatants from both preparations were sterilized by passing 
through a Millipore filter (0.45 m pore size) and stored at −80°C. TNF, 
IL17A, IL1, IFN, TGF1, and IL10 concentrations were determined 
in serum and supernatants using commercial enzyme-linked immuno-
sorbent assay kits (eBioscience) according to the manufacturer’s 
recommendations.
Statistical analysis
For studies in NOD mice, diabetes-free survival in the treatment 
groups was compared by Kaplan-Meier analysis with a log-rank test. 
The Mann-Whitney U test was used to compare insulitis scores among 
different groups.
OPLS-DA was used to integrate principal components analysis 
data and reduce experimental variability and was performed 
using SIMCA PLUS v13.0 (Umetrics). To define the number of 
classes for the OPLS-DA model, we applied partial cross- validation 
and a permutation test to reveal overfitting.
For DBA/1 mice, quantitative variables were tested for normal 
distribution in GraphPad Prism v7. Statistical differences in cytokine 
levels between treatment groups were determined by analysis of 
variance (ANOVA), followed by Bonferroni’s test. Statistical differences 
in the arthritic score and number of Treg cells detected in the lymph 
nodes of RA mice were determined by applying the Kruskal-Wallis 
test followed by Dunn’s multiple comparison test. A value of 
P < 0.05 was considered significant.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/19/eaaz0295/DC1
View/request a protocol for this paper from Bio-protocol.
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